Immunobiologicals in dermatology.
| Autor: | Silva DLFD; Discipline of Dermatology, Hospital de Clínicas, Universidade Estadual de Campinas, Campinas, SP, Brazil. Electronic address: dimitriluz@hotmail.com., Secamilli EN; Discipline of Dermatology, Hospital de Clínicas, Universidade Estadual de Campinas, Campinas, SP, Brazil., Beleli MV; Discipline of Dermatology, Hospital de Clínicas, Universidade Estadual de Campinas, Campinas, SP, Brazil., Massuda JY; Discipline of Dermatology, Hospital de Clínicas, Universidade Estadual de Campinas, Campinas, SP, Brazil., Franca AFEC; Discipline of Dermatology, Hospital de Clínicas, Universidade Estadual de Campinas, Campinas, SP, Brazil., Magalhães RF; Discipline of Dermatology, Hospital de Clínicas, Universidade Estadual de Campinas, Campinas, SP, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Anais brasileiros de dermatologia [An Bras Dermatol] 2022 May-Jun; Vol. 97 (3), pp. 275-283. Date of Electronic Publication: 2022 Mar 18. |
| DOI: | 10.1016/j.abd.2021.05.016 |
| Abstrakt: | Immunobiologicals are a reality in current clinical practice and have increasingly gained space in the inflammatory disease scenario, especially in dermatology, with approved drugs for psoriasis, atopic dermatitis, and hidradenitis suppurativa, in addition to many others undergoing study. It is important for dermatologists to have knowledge of the medications approved in Brazil, for the best management of dermatoses, in addition to the fact that they represent hope for improvement in patients with chronic diseases. (Copyright © 2022 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|